Global X - Genomics & Biotechnology ETF (GNOM) Holdings

이 페이지는 영어 원문에서 AI로 기계 번역되었습니다. 영어 버전이 기준입니다. 영어 버전 읽기

정보 제공만을 목적으로 합니다. 재정적 조언이 아닙니다.

빠른 답변

Global X - Genomics & Biotechnology ETF (GNOM) has a last stored price of $66.46, as of the Oct 26, 2026 trading session. It has a 0.50% expense ratio and $47M in assets under management.

Holdings and weights below are as of Mar 15, 2026. In the stored portfolio snapshot, the largest listed holding is Moderna Inc (MRNA) at 7.86%, and the largest sector allocation is Healthcare at 99.7%.

Global X - Genomics & Biotechnology ETF (GNOM) ETF — Price, Holdings & Analysis

ETF 개요

GNOM aims to track the Solactive Genomics Index, focusing on companies that are expected to benefit from advancements in genomics and biotechnology. This includes firms involved in gene editing, DNA sequencing, and personalized medicine. The fund's strategy involves a concentrated portfolio of 49 holdings, allowing for targeted exposure to key players in the genomics revolution. GNOM's top holdings include Moderna Inc (7.86%), Praxis Precision Medicines Inc Ordinary Shares (6.23%), and Arrowhead Pharmaceuticals Inc (5.69%), reflecting a focus on companies at the forefront of genomic research and development. With a significant allocation to the healthcare sector (99.7%), GNOM provides investors with a specialized tool for participating in the growth of genomics and biotechnology. The remaining 0.3% is allocated to the technology sector. Past performance does not guarantee future results.

위험 지표

GNOM's concentrated portfolio of 49 holdings introduces concentration risk, as the performance of a few key companies can significantly impact the ETF's overall returns. The fund's heavy allocation to the healthcare sector (99.7%) exposes it to sector-specific risks, such as regulatory changes, clinical trial failures, and competition from other biotechnology companies. With a beta of 1.95, GNOM exhibits high volatility compared to the broader market, indicating that it may experience larger price swings. The expense ratio of 0.50% creates an expense drag on returns, which should be considered in the context of the fund's potential performance. Investors should carefully evaluate their risk tolerance and investment objectives before investing in GNOM. Past performance does not guarantee future results.

베타: 1.95

운용보수율

0.50%

GNOM은(는) 무엇을 보유하고 있나요?

보유 종목	비중
Moderna Inc (MRNA)	7.86%
Praxis Precision Medicines Inc Ordinary Shares (PRAX)	6.23%
Arrowhead Pharmaceuticals Inc (ARWR)	5.69%
Illumina Inc (ILMN)	5.13%
Guardant Health Inc (GH)	4.71%
Vertex Pharmaceuticals Inc (VRTX)	4.32%
BioMarin Pharmaceutical Inc (BMRN)	4.31%
Natera Inc (NTRA)	3.91%
BioNTech SE ADR (BNTX)	3.87%
Avidity Biosciences Inc Ordinary Shares (RNAM)	3.75%

보유 종목 및 비중: 2026년 3월 15일 기준. 이 펀드 데이터는 45일 이상 지났습니다. 최신 보유 종목은 발행사에서 확인하세요.

펀드는 어떻게 배분되어 있나요?

섹터	비중
헬스케어	99.7%
기술	0.3%

국가	비중
미국	83.3%
네덜란드	4.3%
독일	3.6%
스위스	3.2%
영국	2.4%
싱가포르	1.6%
중국	1.6%
기타	0.0%

배당수익률

1.30%

iShares Morningstar Small-Cap Growth ETF (JKK) — 0.06% expense ratio
ARK Innovation ETF (ARKK) — 0.75% expense ratio
Invesco QQQ Trust, Series 1 (QQQ) — 0.18% expense ratio
State Street Energy Select Sector SPDR ETF (XLE) — 0.08% expense ratio
WisdomTree Emerging Markets ESG Fund (DVEM) — 0.32% expense ratio
Goldman Sachs ActiveBeta Emerging Markets Equity ETF (GEM) — 0.59% expense ratio
State Street SPDR Dow Jones Industrial Average ETF Trust (DIA) — 0.16% expense ratio
State Street Technology Select Sector SPDR ETF (XLK) — 0.08% expense ratio

Global X - S&P 500 Quality Dividend Covered Call ETF (QDCC) (Equity) — 0.35% expense ratio
Global X Funds - Global X Nasdaq 100 ESG Covered Call ETF (QYLE) (Equity) — 0.61% expense ratio
Global X - MSCI SuperDividend EAFE ETF (EFAS) (Equity) — 0.55% expense ratio
Global X China Innovation ETF (KEJI) (Equity) — 0.75% expense ratio
Global X - Adaptive U.S. Risk Management ETF (ONOF) (Equity) — 0.39% expense ratio
Global X - MSCI Norway ETF (NORW) (Equity) — 0.50% expense ratio

질문 및 답변

What is GNOM and what does it track?

The Global X Genomics & Biotechnology ETF (GNOM) is an exchange-traded fund that seeks to replicate the price and yield performance of the Solactive Genomics Index.

This index is designed to track the performance of companies that are involved in the genomics and biotechnology industries.

What is the expense ratio for GNOM?

The expense ratio for the Global X Genomics & Biotechnology ETF (GNOM) is 0.50%. This means that for every $1000 invested in the fund, $5.00 is used to cover the fund's operating expenses.

While this is higher than some broad market ETFs, it is important to consider the specialized nature of the fund's investment strategy.

What are the top holdings in GNOM?

As of 2026-03-15, the top holdings in the Global X Genomics & Biotechnology ETF (GNOM) are concentrated in leading companies within the genomics and biotechnology industries.

The top three holdings are Moderna Inc (MRNA) at 7.86%, Praxis Precision Medicines Inc Ordinary Shares (PRAX) at 6.23%, and Arrowhead Pharmaceuticals Inc (ARWR) at 5.69%.

Is GNOM a good long-term investment?

Whether GNOM is a suitable long-term investment depends on an individual's investment goals, risk tolerance, and time horizon.

GNOM provides targeted exposure to the genomics and biotechnology sectors, which have the potential for long-term growth due to advancements in personalized medicine and gene editing. However, the fund's concentrated portfolio and sector-specific focus introduce risks that investors should carefully consider.

How does GNOM compare to similar ETFs?

GNOM differentiates itself through its specific focus on genomics and biotechnology companies. While other healthcare or biotechnology ETFs may offer broader exposure, GNOM provides a more targeted approach to investing in the genomics revolution.

GNOM has an expense ratio of 0.50% and an AUM of $0.05 billion.

Does GNOM pay dividends?

Yes, GNOM does pay dividends. As of 2026-03-15, the dividend yield for the Global X Genomics & Biotechnology ETF (GNOM) is 1.30%.

It's important to note that dividend yields can fluctuate based on market conditions and the performance of the underlying holdings.

면책 조항: 이 콘텐츠는 정보 제공만을 목적으로 하며 투자 조언을 구성하지 않습니다. 항상 자체 조사를 수행하고 재정 고문과 상담하십시오.

데이터는 정보 제공만을 목적으로 제공됩니다.

이 페이지는 기계가 작성했으며, 페이지별 사람 검수는 거치지 않았습니다. 편집 관리는 체계 차원에서 이루어집니다: 규칙과 출처를 점검하며, 개별 페이지는 점검하지 않습니다.